
Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial.
ABOS is up 14.65% today. Volume is 1.65M vs a 30-day average of 573.8K (2.87x).

Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial.

Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) reported third-quarter 2026 financial results that exceeded analysts’ expectations, with a smaller net loss compared with the same period…

Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed…
Acumen (ABOS) Q3 loss narrowed vs estimates on zero revenue; cash runway extends to early 2027, with November ALTITUDE-AD Phase 2 data as key catalyst.

Investing.com -- On Monday, Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) reported third quarter results that exceeded analyst expectations.